share_log

This Nasal Spray For Eye Disease Stock Is 'Attractive', Has Potential 160% Upside

This Nasal Spray For Eye Disease Stock Is 'Attractive', Has Potential 160% Upside

这款治疗眼病的鼻喷剂股票很有吸引力，有160%的潜在上涨空间
Benzinga Real-time News ·  2022/08/11 15:14
  • Chardan initiated coverage on Oyster Point Pharma Inc (NASDAQ:OYST) with a Buy rating and a price target of $22.
  • The lead product, Tyrvaya, was approved in October 2021 and generated $1.2 million in the first two months and $2.7 million in 1Q22, its first full quarter. 
  • The company will report Q2 earnings today after the market closes.
  • Chardan says that the prescriber base is bound to grow as Tyrvaya had an estimated commercial coverage for up to 95 million lives at the end of 1Q22, representing 52% of all U.S. commercial lives.
  • In addition, the company expects the Medicare Part D coverage to kick in 2023, further expanding patient access to Tyrvaya.
  • DED represents a large market, with an estimated addressable DED population in the U.S. of up to ~14 million.
  • Approved treatments include Novartis AG's (NYSE: NVS) Xiidra and AbbVie Inc's (NYSE: ABBV) Restasis.
  • The analyst notes that Tervaya's differentiated nasal spray with a quick onset of action could represent an attractive alternative.
  • Overall, Tyrvaya is well positioned to address the limitations of the SOC treatments.
  • Price Action: OYST shares are up 9.77% at $8.43 during the market session on the last check Thursday.
  • 查尔丹在以下日期开始覆盖牡蛎点制药公司(纳斯达克：OYST)评级为买入，目标价为22美元。
  • 主导产品Tyrvaya于2021年10月获得批准，在前两个月创造了120万美元的收入，在22年第一季度创造了270万美元的收入，这是它的第一个完整季度。
  • 该公司将于今日收盘后公布第二季度收益。
  • Chardan表示，处方药的基础肯定会增长，因为截至2012年第一季度末，Tyrvaya的商业保险估计高达9500万人，占美国所有商业生活的52%。
  • 此外，该公司预计联邦医疗保险D部分覆盖范围将于2023年生效，进一步扩大患者获得Tyrvaya的机会。
  • DED代表着一个巨大的市场，据估计，美国可寻址的DED人口高达约1400万。
  • 批准的治疗方法包括诺华制药(纽约证券交易所股票代码：NVS)西德拉和艾伯维公司(纽约证券交易所股票代码：ABBV)Restasis。
  • 这位分析师指出，Tervaya的差异化喷鼻剂起效迅速，可能代表着一种有吸引力的替代方案。
  • 总体而言，Tyrvaya处于有利地位，可以解决SOC治疗的局限性。
  • 价格行动：周四尾盘，OYST股价上涨9.77%，至8.43美元。
声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发